1. Home
  2. GH vs WF Comparison

GH vs WF Comparison

Compare GH & WF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$110.09

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo Woori Financial Group Inc. (each representing three (3) shares of)

WF

Woori Financial Group Inc. (each representing three (3) shares of)

HOLD

Current Price

$57.28

Market Cap

14.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
WF
Founded
2011
1899
Country
United States
South Korea
Employees
N/A
N/A
Industry
Medical Specialities
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
14.6B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
GH
WF
Price
$110.09
$57.28
Analyst Decision
Strong Buy
Analyst Count
21
0
Target Price
$99.48
N/A
AVG Volume (30 Days)
1.9M
55.4K
Earning Date
02-19-2026
10-29-2025
Dividend Yield
N/A
3.75%
EPS Growth
N/A
20.51
EPS
N/A
2.97
Revenue
$902,569,000.00
$8,054,512,650.00
Revenue This Year
$35.00
N/A
Revenue Next Year
$26.80
$4.37
P/E Ratio
N/A
$6.29
Revenue Growth
30.38
23.56
52 Week Low
$34.80
$29.44
52 Week High
$113.91
$60.48

Technical Indicators

Market Signals
Indicator
GH
WF
Relative Strength Index (RSI) 63.59 47.22
Support Level $106.42 $56.63
Resistance Level $113.91 $60.48
Average True Range (ATR) 3.97 1.27
MACD 0.63 -0.23
Stochastic Oscillator 77.16 22.54

Price Performance

Historical Comparison
GH
WF

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About WF Woori Financial Group Inc. (each representing three (3) shares of)

Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.

Share on Social Networks: